November 4, 2012. The government-backed Biomedical Catalyst programme announced major funding for the ground-breaking Q-CANCER project which will integrate QuantuMDx Group’s rapid on-chip lab processes and develop the first sub-20 minute tumour profiler. When commercialized within the next 3 years, the device will have a dramatic impact on the rapid and accurate diagnosis and staging of cancer. Q-CANCER has the potential to ease the suffering and prolong the lives of the 12.7m newly diagnosed cancer sufferers, globally, by enabling surgeons to immediately remove most, if not all of the tumour and oncologists to prescribe the correct treatment regime according to the type of cancer developed.
The £2.8m project, with £1.4m awarded by the Biomedical Catalyst, will further develop QuantuMDx Group’s platform technology to build a low cost, fully integrated, sample-to-result benchtop device that will enable either histopathologists themselves or lab technicians, to perform multiplex genotyping and tumour staging and profiling, within minutes. They will also be able to use formalin fixed or fresh tissue samples, thus allowing for easy integration into standard practice.
The Project brings together the nanotechnology and chemistry expertise of Newcastle University with the specialist Oncology expertise and cancer networks of Leaders in Oncology Limited (London), the sample prep technology of Magna Parva Limited (Leicester) and the design and engineering expertise of The Technology Partnership (Cambridge).